Hydrogel based drug delivery system market

Hydrogel-Based Drug Delivery System Market, by Source (Natural, Synthetic, and Hybrid), by Route of Delivery (Oral Cavity, Subcutaneous, Topical, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

May 2022
CMI5022
206 Pages
Excel & Pdf
Pharmaceutical

Summary

Conventional drug delivery approaches have issues pertaining to repeated dosing and systemic toxicity. Hence, new drug delivery systems are now developed for overcoming these disadvantages and optimizing the therapeutic benefits of the drugs. Hydrogels have a wide range of biomedical applications other than drug delivery such as manufacturing contact lenses, wound dressings, and tissue engineering. The mechanism of drug delivery by using hydrogel involves diffusion-based drug release from the hydrogel mesh or pores filled with water. This reservoir delivery system ensures time-independent and constant drug release. Different hydrogel products are administered by various routes of administration such as peroral, rectal, ocular, and transdermal among others. The hydrogel systems have several therapeutic applications such as for treating inflammatory diseases, cardiac illness & cancer, and diabetic foot ulcer among others.

The global hydrogel-based drug delivery system market is estimated to be valued at US$ 4,785.4 million in 2022 and is expected to exhibit a CAGR of 6.9% during the forecast period (2022-2030).

Figure 1. Global Hydrogel-Based Drug Delivery System Market in Terms of Value (US$ million), By Region, 2022

Increasing application of hydrogel-based drug delivery systems to treat various disorders such as metabolic syndrome is expected to drive the global hydrogel-based drug delivery system market growth during forecast period.

Researchers across the world are creating new drug delivery models for efficient drug delivery which is driving the growth of the hydrogel-based drug delivery system market over the forecast period. For instance, in 2021, researchers from Marine College, Shandong University, China, and Universidad de Talca, Chile demonstrated that the use of hydrogel-based controlled release system increased the therapeutic efficacy in various components of the metabolic syndrome. The study concluded that these hydrogel systems had various advantages such as sustained pharmacological release which ensured a safe route of administration of drug and avoided the need for repeated doses.

Hydrogel-Based Drug Delivery System Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 4,785.4 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	6.9%	2030 Value Projection:	US$ 8,187.6 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Source: Natural, Synthetic, Hybrid By Route of Delivery: Oral Cavity, Subcutaneous, Topical, Others
Companies covered:	Johnson & Johnson, Bausch & Lomb, Ocular Therapeutix, Inc, Tolmar Pharmaceuticals, Inc., Ashland, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Micropore Technologies, Neurelis, Inc., and ProLynx Inc.
Growth Drivers:	Increasing application of hydrogel-based drug delivery systems to treat various disorders such as metabolic syndrome Increasing approval of new hydrogel-based products
Restraints & Challenges:	Limitations such as slow responsiveness and possibility of drug inactivation associated with hydrogel-based drug delivery system

Figure 2. Global Hydrogel-Based Drug Delivery System Market Share in Terms of Value (US$ Mn), By Route of Delivery, 2022

The increasing approval of new hydrogel-based products is expected to drive the market growth over the forecast period.

New products based on hydrogel drug delivery systems are receiving marketing authorization which can be further contributing to the market growth. For instance, in April 2019, the U.S. Food and Drug Administration approved Plenity manufactured by Gelesis a biotechnology company for the treatment of obesity. Plenity is a non-systemic, oral formulation made up of superabsorbent hydrogel which is used for weight management in adults. The capsule works by inducing a feeling of fullness so that individuals eat less and eventually aid in losing weight. Hence, such approvals for drugs based on hydrogel technology are expected to drive the market growth over the forecast period.

Global Hydrogel-Based Drug Delivery System Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus Disease (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 409 million cases and 5.8 million deaths due to coronavirus disease (COVID-19) were reported up till 13^th, February 2022 across the globe.

The Covid-19 pandemic has made the need for understanding biocompatible polymers as support material for controlled drug delivery especially for organohydrogels. Several studies are conducted for characterization of novel organohydrogel as a natural drug carrier or release material. For instance, in January 2021, researchers synthesized various new polymeric materials such as hydrogels, organohydrogels, and gels for investigating their use as drug release systems. The study concluded that organohydrogels can be used as drug carrier and controlled drug release materials. Hence, the high R&D activities in the pandemic for understanding the potential use of hydrogels in drug delivery is positively impacting the market growth over the forecast period.

Global Hydrogel-Based Drug Delivery System Market: Restraint

The limitations associated with hydrogel-based drug delivery system is likely to hamper the market growth. For instance, the common limitations of hydrogels as drug delivery systems are non-biodegradable properties of some hydrogels, slow responsiveness, possibility of drug inactivation, and rapid release of drug owing to hydrogel swelling and bursting. Hence, overcoming these challenges by different approaches is required for ensuring it as efficient drug delivery method.

Key Players

Major players operating in the global hydrogel-based drug delivery system market include Johnson & Johnson, Bausch & Lomb, Ocular Therapeutix, Inc, Tolmar Pharmaceuticals, Inc., Ashland, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Micropore Technologies, Neurelis, Inc., and ProLynx Inc.

Table of Content

Table of Contents

*Browse 44 market data tables and 49 figures on "Global Hydrogel-Based Drug Delivery System Market” - Forecast to 2030

Segmentation

Detailed Segmentation:

Global Hydrogel-Based Drug Delivery System Market, By Source
- Natural
  - Synthetic
  - Hybrid
Global Hydrogel-Based Drug Delivery System Market, By Route of Delivery
- Oral Cavity
- Subcutaneous
- Topical
- Others
Global Hydrogel-Based Drug Delivery System Market, By Region:
- North America
  - By Source
    - Natural
    - Synthetic
    - Hybrid
  - By Route of Delivery
    - Oral Cavity
    - Subcutaneous
    - Topical
    - Others
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Source
    - Natural
    - Synthetic
    - Hybrid
  - By Route of Delivery
    - Oral Cavity
    - Subcutaneous
    - Topical
    - Others
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Source
    - Natural
    - Synthetic
    - Hybrid
  - By Route of Delivery
    - Oral Cavity
    - Subcutaneous
    - Topical
    - Others
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Source
    - Natural
    - Synthetic
  - By Route of Delivery
    - Oral Cavity
    - Subcutaneous
    - Topical
    - Others
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Source
    - Natural
    - Synthetic
    - Hybrid
  - By Route of Delivery
    - Oral Cavity
    - Subcutaneous
    - Topical
    - Others
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Source
    - Natural
    - Synthetic
    - Hybrid
  - By Route of Delivery
    - Oral Cavity
    - Subcutaneous
    - Topical
    - Others
  - By Country/Region
    - South Africa
    - Central Africa
    - North Africa

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global hydrogel-based drug delivery system market during the forecast period (2022-2030)?

The market is estimated to be valued at US$ 4,785.4 million in 2022 and is expected to exhibit a CAGR of 6.9% between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increasing approval of new hydrogel-based products is expected to drive the market growth during the forecast period.

Which is the leading route of delivery segment in the market?

Oral cavity is expected to hold a major market share during the forecast period in the route of delivery segment.

What are the key factors hampering growth of the market?

The major factor hampering growth of the market include limitations such as slow responsiveness and possibility of drug inactivation associated with hydrogel-based drug delivery system.

Which are the major players operating in the market?

Major players operating in the market include Johnson & Johnson, Bausch & Lomb, Ocular Therapeutix, Inc, Tolmar Pharmaceuticals, Inc., Ashland, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Micropore Technologies, Neurelis, Inc., and ProLynx Inc.